Mirvetuximab soravtansine [MIR1]

For treating folate receptor-alpha-positive platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer where the following criteria have been met:

1. This application is being made by and the first cycle of systemic anti-cancer therapy will be prescribed by a consultant, or internally accredited oncology specialty trainee, specifically trained and assessed in the use of systemic anti-cancer therapy.
2. This patient has a histological diagnosis of high-grade serous epithelial ovarian, primary peritoneal, or fallopian tube cancer.
3. The patient has platinum resistant disease. Note - this is defined as recurrence/progression less than SIX months after the date on which the last platinum containing chemotherapy was given.
4. The patient has folate receptor-alpha (FRα) positive disease Note – this is defined as > or = to 75% of tumour cells showing moderate (2+) and/or strong (3+) membrane staining using an approved assay.
5. This patient has received either ONE, TWO, or THREE prior lines of systemic treatment for their disease. Please mark below how many prior lines of treatment have been received:

• ONE prior line
• TWO prior lines
• THREE prior lines

6. The patient has an ECOG performance status of 0 or 1. Please mark below the performance status of the patient:

• ECOG PS 0
• ECOG PS 1

7. Treatment with mirvetuximab soravtansine will be given until disease progression, unacceptable toxicity, or withdrawal of patient consent, whichever of these events occurs first.
8. The prescribing clinician understands that given the potentially necessary frequency and duration of treatment breaks during treatment with mirvetuximab soravtansine, this indication is exempt from NHS England’s treatment break policy

Note

Note: if there is disease progression during a treatment break from mirvetuximab soravtansine, treatment with mirvetuximab soravtansine must be discontinued.

9. The use of mirvetuximab soravtansine will be otherwise used as per its Summary of Product Characteristics (SPC).

CDF funded From: 04 June 2026

Additional information

Form version: -

CDF Managed Access: No

NICE Technology Appraisal: NA (NA)

Current Form Version

Important

This is an older version of the form. To view the most up to date form follow this link

Older Form Versions

There are previous versions of this form. These may not all be available on this site.